Peregrine Pharmaceuticals Reports Positive Early Results In Phase II Study Of Bavituximab In Breast Cancer
Jul 4th 2008Drug InformationBreast Cancer
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical trial in patients with metastatic breast cancer. The trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of a combination of bavituximab and docetaxel in metastatic breast cancer patients.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
